ClinicalTrials.Veeva

Menu
I

Integrative Clinical Trials, LLC | Brooklyn, NY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Troriluzole
Piromelatine
LY3314814
ATH-1017
Eptinezumab
Pimavanserin
Cariprazine
Lanabecestat
Aticaprant
Simufilam

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 46 total trials

A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011)

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer...

Enrolling
Alzheimer Disease 6
Cognitive Impairment
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling
Anhedonia
Depressive Disorder, Major
Drug: Aticaprant
Other: Placebo

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective sero...

Enrolling
Anhedonia
Depressive Disorder, Major
Other: Placebo
Drug: Aticaprant

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or...

Enrolling
Chronic Migraine
Episodic Migraine
Biological: IPN10200 dose B
Biological: IPN10200

This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is t...

Enrolling
Depressive Disorder, Major
Drug: Placebo matching BI 1569912
Drug: BI 1569912

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Active, not recruiting
Alzheimer Disease
Drug: Simufilam

Randomized efficacy and safety study of piromelatine 20 mg versus placebo in participants with mild dementia due to Alzheimer's disease (AD) who are...

Active, not recruiting
Alzheimer's Disease
Drug: Piromelatine 20 mg
Drug: Placebo

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: Simufilam

A Randomized, Double-blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients with Early Alzheimer's Di...

Active, not recruiting
Alzheimer's Disease
Drug: BPN14770
Drug: Placebo

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

Trial sponsors

Biohaven logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Acadia Pharmaceuticals logo
AstraZeneca logo
Athira Pharma logo
C
Lundbeck logo
N
Otsuka logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems